Molecular Vision Appoints Peter Woodford as Chairman

Strengthens Board in Preparation for Commercialisation

16-Feb-2009 - United Kingdom

Molecular Vision, a developer of quantitative point-of-care (POC) diagnostic devices, has announced the appointment of Peter Woodford as Non-Executive Chairman with immediate effect. The appointment serves to strengthen the Board as the Company prepares to commercialise its novel detection technology, focussing on low cost POC diagnostic tests in a miniaturised, easy-to-use, disposable format.

Mr Woodford has over 35 years’ experience in the diagnostics industry. Most recently he spent 15 years with Roche Diagnostics/Boehringer Mannheim, where he was responsible for a £1.2 billion budget for Roche Diabetes Care global strategic and commercial activities.

Molecular Vision’s previous Chairman, Dr Chris Wright, will continue to serve on the Board as a Non-Executive Director.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures